NCT00485030

Diffuse Type In-Stent Restenosis After Drug-Eluting Stent

Comparison Between Drug-Eluting Stents for the Treatment of the Diffuse Type In-Stent Restenosis After Drug-Eluting Stents Implantation: Sirolimus-Eluting vs. Paclitaxel-Eluting Stents

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Seung-Jung Park · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the best therapeutic option for the treatment of diffuse type post-drug-eluting stent restenosis.

Detailed description

Despite a significant reduction of angiographic restenosis and the need for repeat revascularization after introduction of DES, post-DES restenosis still occur and the treatment for DES failure is challenging. However, there have been little data for therapeutic strategy for post-DES restenosis, especially diffuse type ISR. Therefore, we need the well-designed randomized trial to achieve the best therapeutic option for the treatment of diffuse type post-DES restenosis.

Conditions

• In-stent Restenosis

Interventions

Type	Name	Description
DEVICE	Cypher	sirolimus-eluting stent
DEVICE	Xience-V	everolimus-eluting stent

Timeline

• Start date: 2007-03-01
• Primary completion: 2011-09-01
• Completion: 2011-10-01
• First posted: 2007-06-12
• Last updated: 2012-08-08

Locations

15 sites across 1 country: South Korea